Liposheres as a Novel Carrier for Lipid Based Drug Delivery: Current and Future Directions

Abstract

Researchers are facing challenges to develop robust formulation and to enhance the bioavailability of poorly water-soluble drugs towards clinical applications. The development of new drug molecule alone is not adequate to assure ample pharmacotherapy of various diseases. Considerable results obtained from in vitro studies are not supported by in vivo data due to inadequate plasma drug concentrations. This may occur due to limited drug solubility and absorption. To resolve these problems, development of new drug delivery systems will be a promising approach. One of the promising pharmaceutical strategies is the use of lipospheres drug delivery system to deliver the poorly water-soluble drugs. Therefore, the present review described the methodology for manufacturing of lipospheres and factors influencing the formulation to deliver the drugs to the targeted site. Apart from that, this review also enlisted briefly the various applications of liposphers in medical and biomedical fields and critically discussed the recent patent system.

The Amalgamation of Risk Assessment Using Quality by Design Principles and Prediction of Regression Models in the Development of Dexmedetomidine-loaded Lipospheres for Intra-articular Administration

“…A single bolus injection of antibiotics and anti-inflammatory agents could sustain the drug release for 3 to 5 days using lipospheres. 16 Composition of lipospheres is such that it drug tends to remain stable in the honey comb architecture leading to sustained drug release, the system allows high payload of drugs and the components have minimal toxicity. 17 Delivery system based on lipospheres for DEX using intraarticular administration is not reported.…”

Development of a Multifunctional Bioerodible Nanocomposite Containing Metronidazole and Curcumin to Apply on L-PRF Clot to Promote Tissue Regeneration in Dentistry

“…Due to its lipophilic nature and physicochemical instability [ 25 ], CUR needs to be included in a pharmaceutical formulation to be available in aqueous environments. For instance, CUR can be loaded in lipid-based colloidal dispersions, suitable formulations to overcome problems of degradation, poor solubility, and penetration inside the tissue [ 26 , 27 ].…”

Εφαρμογές του Gefitinib και συμπλοκών μικροεγκλεισμού Gefitinib κυκλοδεξτρινών

“…Ορισμένα λιποσώματα φέρουν στην επιφάνειά τους λειτουργικές ομάδες, όπως γλυκολιπίδια, σιαλικό οξύ και PEG, οι οποίες με κατάλληλη τροποποίηση μπορούν να προσδένουν άλλα μόρια, όπως μονοκλωνικά αντισώματα που στοχεύουν συγκεκριμένα αντιγόνα και επομένως κύτταρα. Έχουν παραχθεί συμπλέγματα λιποσωμάτων με CyDs για τη βελτίωση των ιδιοτήτων των επιμέρους συστατικών του συμπλόκου[323,324,[329][330][331][332][333][334][335][336][337][338][339][340]. 1 ανάκλιντρου (εικόνα 6.1), οι οποίες συνδέονται μεταξύ τους με α(1)(2)(3)(4) γλυκοζιτικούς δεσμούς[341,342].…”